Skip to main content
. 2017 Apr 6;7:682. doi: 10.1038/s41598-017-00839-9

Figure 1.

Figure 1

Bortezomib and leucovorin reduce cell viability of HCT116 and HT29 cells. (A) Schematic presentation of the screening of the Approved Oncology Drugs Set VI from NCI. (B) Cell viability of HCT116 cells treated with a single drug or with the addition of leucovorin. (C,D) Percent viability of HCT116 (B) and HT29 (C) cells upon treatment with the combination of bortezomib (BTZ, 3 nM to 300 nM) and leucovorin (LV, 10 µM) compared to those treated with bortezomib alone for 24 h and 48 h. Cell viability was determined by CellTiter-Glo assays (C and D).